Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D Protected Classes: Stakeholders Wary About “Expert Panel” Role

Executive Summary

The roles of an outside contractor and expert panel in implementing Medicare Part D's policy on protected drug classes are sparking questions and concerns among stakeholders

You may also be interested in...



CMS Opens Way To Add, Or Subtract, Protected Classes In Part D Formularies

CMS is creating a multi-step process that will give outside experts and the public a role in adding or subtracting "protected" drug classes in Medicare Part D, as well as making exceptions to the rule that all drugs must be covered in a protected class

Medicare Bill Allows Changes To Part D Protected Classes, Via Rule-Making

The new statutory requirement that Medicare drug plans cover all drugs in protected drug classes includes a hint of possible flexibility for interested stakeholders - the designated groups could be expanded or subtracted, though only through a formal regulatory process

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS050695

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel